| Email not displaying properly? View email in your browser |
|
| PROJECTS
|
 |
BD Invests $100 Million to Expand Insulin Syringe Manufacturing at Nebraska Plant
BD (Becton, Dickinson and Company), a leading global medical technology company announced it is investing $100 million in its Holdrege, Neb. facility to expand capacity for its insulin syringe manufacturing operations.
The investment will be used for new technology and manufacturing equipment to expand capacity for BD insulin syringes. BD already produces more than 2 billion insulin syringes each year...
more... |
 |
| Featured Products |
|
 |
| Blender Module
|
Matcon IBCs become portable blending vessels when used with our IBC Blender. High OEE (Overall Equipment Effectiveness) rates are achieved as filling, emptying and cleaning take place off-line – providing a greater potential than any other blending technology. One IBC Blender can often surpass...
more... |
|
|
 |
| Neo TOP X |
As a result of the increasing market and product segmentation,in addition to the way the modern medicines work,the prevalent extensive variety of secondary packaging is constantly expanding.This is why the flexibility and over-all efficiency of the packaging process is of...
more... |
|
|
 |
| Cresols
|
We offer MPC from Ruetgers Aromatic Chemicals GmbH, Germany ranging from 45-98%. We also offer o-cresol and cresol-phenol blends. Application for these products is found in making wire enamels, anti-oxidants and flame retardents.Commencing in the year 1951 as a as a marketing...
more... |
|
|
| Industry Updates |
|
| News |
|
Allergan To Buy Zeltiq Aesthetics For $2.48 Billion
|
|
Botox maker Allergan Plc agreed to pay $2.48 billion in cash for Zeltiq Aesthetics Inc, adding a system that it says helps people slim down by freezing fat away to the company's line-up of aesthetic products.
Allergan said it would benefit from the cross-selling opportunities for consumers of Zeltiq's CoolSculpting System, which uses cooling to... |
|
|
| Press Releases |
|
Akebia Licenses Portfolio Of Novel HIF Compounds...
|
|
Akebia Therapeutics, Inc.,a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF),today announced that it has entered into an exclusive agreement with the Janssen Pharmaceutica, NV, one of... |
|
|
|
|
www.pharmaceutical-tech.com - Owned by Ochre Media Pvt. Ltd.
Media Resource Centre, 2nd Floor, Oxford Plaza, Secunderabad - 500 003, Telangana, India
Tel: +91 40 4961 4567 | Fax: +91 40 4961 4555 |
|
